Our new strategy of making use of commonly overexpressed Cyclooxygenase-2 for anti-cancer purpose represents a paradigm shifting concept as it challenges the conventional Cyclooxygenase-2 inhibition strategy in cancer treatment. The gene discussed is PTGS2; the disease is cancer.